Startup inhaled drug developer AeroRx Therapeutics and nebulizer maker HCmed Innovations have announced that they will partner on development of a nebulized LABA/LAMA inhalation solution for the treatment of COPD. AeroRx is a spinoff of iPharma Labs, which was acquired by Kindeva Drug Delivery earlier this year. In March 2022, HCmed announced that it was partnering with Formosa Laboratories and Formosa Pharmaceuticals to create a new inhalation CDMO.
According to the announcement, the new product will include a formulation developed by AeroRx delivered via HCmed’s AdheResp breath-actuated nebulizer, and AeroRx is expected to initiate a PK/PD study of the inhalation solution using the AdheResp nebulizer in 2023 to support a 505(b)(2) NDA submission.
HCmed CEO Jason Cheng commented, “We are excited to announce our partnership with AeroRx. The AeroRx team has extensive experience in the development of respiratory drugs, while at HCmed we can support our partners to develop drug-nebulizer combination products with our proprietary breath-actuated mesh nebulizer platform. The product of our collaboration will provide COPD patients with an effective inhaled LABA/LAMA combination drug, which will reinforce patients’ treatment adherence and improve their quality of life.”
AeroRx President Keith Ung added, “We too are enthusiastic about this partnership. Breath-actuated vibrating mesh delivery of inhaled therapeutics is the wave of the future for many therapeutics and HCmed has become one of the leaders in this elegant inhaler device technology.”
Read the HCmed press release.
